Navigation Links
Multiple Sclerosis Drug Trial Criteria to Be Redefined

The tragic death of Anita Louise, a participant of the experimental multiple sclerosis drug trial in 2002 has been brought back to focus by two neurologists from Stanford University//. The authors warn about the dangers associated with drug testing, more so when the adverse effects of the experimental drug is unknown.

The drug natalizumab, marketed under the brand name was granted fast track status by the FDA in 2004. Soon after the approval, the drug use was found to be associated with a potentially fatal infection, progressive multifocal leukoencephalopathy (PML). The observation of infection in a patient who was devoid of the disease prompted the researchers to investigate further.

The researchers argue that healthy volunteers should not be allowed to participate in such drug trials, as they do not derive any benefit out of it. Furthermore, they feel that drugs associated with a risk of death should only be used in patients diagnosed with the disease, after all possible treatments have been found to be ineffective.

Multiple sclerosis is the manifestation of myelin sheath destruction surrounding the nerve cells. The immune system cells attack the myelin sheath, eventually leading to loss of control over motor function and even paralysis. The drug was found to block this effect.

It was highlighted that the inhibition of immune cells, could lead to an increased susceptibility to infections. In fact, PML is an infection that usually affects immunocompromised individuals such as transplant recipients, AIDS victims etc.

The drug was withdrawn from clinical use three months following its approval. With this being the situation, the FDA has taken up the re-approving of the drug as a single therapy. The advisory panel members would get together on the 7th and 8th of March to discuss the issue.

'A big mistake was made in these trials that, in my opinion, is easily preventable. All they need to do is t ighten up entry criteria into multiple sclerosis clinical trials and we could avoid similar types of problems in other trials,' concluded Langer-Gould, one f the senior researchers involved in the study.


'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... BROOKLINE, MA (PRWEB) , ... April 28, 2016 , ... ... his revolutionary work in the emerging field of biomechatronics, technology that marries human physiology ... the MIT Media Lab. He is also the Founder of BionX , a ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... 28, 2016 , ... One way to ignore solid evidence is to dismiss ... we toss the baby out with the bathwater when we ignore all studies because ... studies and otherwise making better use of education policy research. , “When readers heed ...
(Date:4/28/2016)... ... April 28, 2016 , ... USA Medical Card reminds us that May is National ... stroke is the fourth leading cause of death in the United States; someone has one ... quarter of them in individuals under 65 years old. A stroke is when blood ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
Breaking Medicine Technology: